Pharma M&A is hitting top gear, and merger Monday brought two new deals in the space.
Roche Bets Big On Gene Therapy
Swiss pharma giant Roche Holdings AG Basel ADR (OTC: RHHBY) announced early Monday a deal to buy U.S.-based gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE) for $114.50 per share in cash, or a total equity value of $4.8 billion, including about $500 million of net cash expected at close.
The per share value represents a 122.07-percent premium over Spark's Friday closing price of $51.56.
Roche will commence a tender offer to acquire all outstanding shares of Spark, and upon completion will acquire the remaining untendered shares at the same price through a second step merger.
"With its worldwide reach and extensive resources, Roche will help us accelerate the development of more gene therapies for more patients for more diseases and further expedite our vision of a world where no life is limited by genetic disease," Spark CEO Jeffrey Marrazzo said in a statement, explaining the logic behind the proposed combination.
Following the consummation of the transaction, Spark will continue to operate out of Philadelphia as an independent company within the Roche Group.
The deal is expected to close in the second quarter of 2019.
Spark has a gene therapy, Luxturna, in the market, which is indicated to treat a rare gene-induced retinal disease that can lead to blindness.
It has two advanced gene therapy candidates in the pipeline for hemophilia: SPK-9011 for hemophilia B and SPK-8011 for hemophilia A.
Ipsen to Buy Rare Bone Disorder Drug Company Clementia
IPSEN S A/S ADR (OTC: IPSEY) said it has negotiated a deal to buy Canadian biotech Clementia Pharmaceuticals Inc (NASDAQ: CMTA) for an upfront payment of $25 per share in cash or $1.04 billion in total, and a contingent value right of $6 per share related to multiple osteochondromas, or MO, for a total deal value of $1.31 billion.
"The initial cash consideration represents a premium of 77 percent to Clementia's 30-day volume-weighted average stock price," Ipsen said.
Clementia has a late-stage clinical asset, palovarotene, which is a retinoic and receptor gamma selective antagonist forfibrodysplasia ossificans progressive, or FOP; MO; and other diseases. FPO and MO are two ultra-rare/rare and severely disabling bone disorders for which there are no current treatment options.
The company is likely to submit a NDA for the pipeline asset in the second half of 2019, with a potential commercial launch estimated in mid-2020.
The boards of both companies have approved the transaction, and contingent on the satisfaction of all necessary approvals, the deal is expected to close in the second half of the year.
In pre-market trading Monday, Spark shares were soaring 120.87 percent to $113.88 and Clementia was rallying 75.6 percent to $26.20.
Karyopharm Shares Nosedive On Tough FDA Briefing For Multiple Myeloma Drug
See more from Benzinga
- The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
- The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.